Discovery and validation of dominantly inherited Alzheimer’s disease mutations in populations from Latin America
-
Published:2022-08-05
Issue:1
Volume:14
Page:
-
ISSN:1758-9193
-
Container-title:Alzheimer's Research & Therapy
-
language:en
-
Short-container-title:Alz Res Therapy
Author:
Takada Leonel Tadao,Aláez-Verson Carmen,Burgute Bhagyashri D.,Nitrini Ricardo,Sosa Ana Luisa,Castilhos Raphael Machado,Chaves Marcia Fagundes,Longoria Erika-Mariana,Carrillo-Sánchez Karol,Brucki Sonia Maria Dozzi,Flores-Lagunes Luis Leonardo,Molina Carolina,Olivares Marcos Jimenez,Ziegemeier Ellen,Petranek Jennifer,Goate Alison M.,Cruchaga Carlos,Renton Alan E.,Fernández Maria Victoria,Day Gregory S.,McDade Eric,Bateman Randall J.,Karch Celeste M.,Llibre-Guerra Jorge J.,
Abstract
Abstract
Background
In fewer than 1% of patients, AD is caused by autosomal dominant mutations in either the presenilin 1 (PSEN1), presenilin 2 (PSEN2), or amyloid precursor protein (APP) genes. The full extent of familial AD and frequency of these variants remains understudied in Latin American (LatAm) countries. Due to the rare nature of these variants, determining the pathogenicity of a novel variant in these genes can be challenging. Here, we use a systematic approach to assign the likelihood of pathogenicity in variants from densely affected families in Latin American populations.
Methods
Clinical data was collected from LatAm families at risk for DIAD. Symptomatic family members were identified and assessed by local clinicians and referred for genetic counseling and testing. To determine the likelihood of pathogenicity among variants of unknown significance from LatAm populations, we report pedigree information, frequency in control populations, in silico predictions, and cell-based models of amyloid-beta ratios.
Results
We identified five novel variants in the presenilin1 (PSEN1) gene from Brazilian and Mexican families. The mean age at onset in newly identified families was 43.5 years (range 36–54). PSEN1 p.Val103_Ser104delinsGly, p.Lys395Ile, p.Pro264Se, p.Ala275Thr, and p.Ile414Thr variants have not been reported in PubMed, ClinVar, and have not been reported in dominantly inherited AD (DIAD) families. We found that PSEN1 p.Val103_Ser104delinsGly, p.Lys395Ile, p.Pro264Se, and p.Ala275Thr produce Aβ profiles consistent with known AD pathogenic mutations. PSEN1 p.Ile414Thr did not alter Aβ in a manner consistent with a known pathogenic mutation.
Conclusions
Our study provides further insights into the genetics of AD in LatAm. Based on our findings, including clinical presentation, imaging, genetic, segregations studies, and cell-based analysis, we propose that PSEN1 p.Val103_Ser104delinsGly, p.Lys395Ile, p.Pro264Se, and p.Ala275Thr are likely pathogenic variants resulting in DIAD, whereas PSEN1 p.Ile414Thr is likely a risk factor. This report is a step forward to improving the inclusion/engagement of LatAm families in research. Family discovery is of great relevance for the region, as new initiatives are underway to extend clinical trials and observational studies to families living with DIAD.
Publisher
Springer Science and Business Media LLC
Subject
Cognitive Neuroscience,Neurology (clinical),Neurology
Reference47 articles.
1. Brayne C, Miller B, Robinson L, Jagger C, Barnes L, Arthur A, et al. Dementia and aging populations—A global priority for contextualized research and health policy. PLOS Med. 2017;14:e1002275. Available from:. https://doi.org/10.1371/journal.pmed.1002275. 2. Prince M, Comas-Herrera A, Knapp M, Guerchet M, Karagiannidou M. World Alzheimer Report 2016 Improving healthcare for people living with dementia, Coverage, Quality and costs now and in the future, vol. 2016. p. 1–140. Available from: https://www.alz.co.uk/research/world-report-2016 3. Barnes DE, Yaffe K. The projected effect of risk factor reduction on Alzheimer’s disease prevalence. Lancet Neurol. 2011;10:819–28. 4. Cummings J, Aisen PS, DuBois B, Frölich L, Jack CR, Jones RW, et al. Drug development in Alzheimer’s disease: the path to 2025. Alzheimers Res Ther. 2016;8:39 Available from: http://www.ncbi.nlm.nih.gov/pubmed/27646601. [cited 2019 Apr 26]. 5. Livingston G, Huntley J, Sommerlad A, Ames D, Ballard C, Banerjee S, et al. Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. Lancet. 2020; Available from: https://linkinghub.elsevier.com/retrieve/pii/S0140673620303676. [cited 2020 Aug 2].
Cited by
4 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|